NASDAQ:CGEN Compugen (CGEN) Stock Price, News & Analysis → Collapse of the Petrodollar (From Colonial Metals) (Ad) Free CGEN Stock Alerts $2.01 -0.08 (-3.83%) (As of 05/10/2024 ET) Add Compare Share Share Today's Range$1.91▼$2.1150-Day Range$1.88▼$2.9552-Week Range$0.53▼$3.03Volume271,884 shsAverage Volume312,207 shsMarket Capitalization$174.12 millionP/E RatioN/ADividend YieldN/APrice Target$4.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Compugen alerts: Email Address Compugen MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside99.0% Upside$4.00 Price TargetShort InterestBearish2.25% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.83Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom $0.02 to ($0.27) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.13 out of 5 starsMedical Sector793rd out of 925 stocksBiological Products, Except Diagnostic Industry133rd out of 154 stocks 3.5 Analyst's Opinion Consensus RatingCompugen has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCompugen has received no research coverage in the past 90 days.Read more about Compugen's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted2.25% of the outstanding shares of Compugen have been sold short.Short Interest Ratio / Days to CoverCompugen has a short interest ratio ("days to cover") of 4.Change versus previous month Previous Next 0.0 Dividend Strength Dividend YieldCompugen does not currently pay a dividend.Dividend GrowthCompugen does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CGEN. Previous Next 2.7 News and Social Media Coverage News SentimentCompugen has a news sentiment score of 0.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Compugen this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for CGEN on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Compugen to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Compugen insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.50% of the stock of Compugen is held by insiders.Percentage Held by InstitutionsOnly 12.22% of the stock of Compugen is held by institutions.Read more about Compugen's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Compugen are expected to decrease in the coming year, from $0.02 to ($0.27) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Compugen is -9.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Compugen is -9.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCompugen has a P/B Ratio of 2.64. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Compugen's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaTech GIANT’s Plans to Revolutionize Crypto…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. About Compugen Stock (NASDAQ:CGEN)Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.Read More CGEN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CGEN Stock News HeadlinesMay 10, 2024 | americanbankingnews.comCompugen (NASDAQ:CGEN) Stock Passes Above 200-Day Moving Average of $1.78May 6, 2024 | prnewswire.comCompugen to Release First Quarter 2024 Results on Monday, May 20, 2024May 11, 2024 | Colonial Metals (Ad)Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. May 1, 2024 | americanbankingnews.comCompugen (NASDAQ:CGEN) Share Price Crosses Above 200-Day Moving Average of $1.73April 29, 2024 | finance.yahoo.comWe're Not Worried About Compugen's (NASDAQ:CGEN) Cash BurnApril 25, 2024 | prnewswire.comCompugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024April 15, 2024 | stocknews.com3 Biotech Stocks with Potential Gains - Watch or Buy?April 11, 2024 | investing.comCompugen reports progress on cancer therapy COM503May 11, 2024 | Colonial Metals (Ad)Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. April 10, 2024 | prnewswire.comCompugen Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503April 3, 2024 | finance.yahoo.comCompugen to Participate in Two Upcoming Investor ConferencesApril 2, 2024 | finance.yahoo.comIs Compugen Ltd. (NASDAQ:CGEN) Trading At A 31% Discount?March 16, 2024 | markets.businessinsider.comTruist Financial Reaffirms Their Buy Rating on Compugen (CGEN)March 11, 2024 | finance.yahoo.comCompugen Selected for two Oral Presentations at the Keystone Symposium on Cancer ImmunotherapyMarch 8, 2024 | seekingalpha.comCompugen Ltd. (CGEN) Q4 2023 Earnings Call TranscriptMarch 8, 2024 | markets.businessinsider.comBuy Rating Justified by Compugen’s Positive Clinical Outlook and Financial StabilityMarch 7, 2024 | finance.yahoo.comCompugen Ltd. (NASDAQ:CGEN) Q4 2023 Earnings Call TranscriptMarch 7, 2024 | finanznachrichten.deCompugen Ltd.: Compugen Reports Fourth Quarter and Full Year 2023 ResultsMarch 6, 2024 | prnewswire.comCompugen to Present Data Reflecting its Diversified Immuno-Oncology Pipeline at AACR 2024March 5, 2024 | msn.comCGEN Stock Earnings: Compugen Misses EPS, Beats Revenue for Q4 2023March 5, 2024 | sfgate.comCompugen: Q4 Earnings SnapshotMarch 5, 2024 | prnewswire.comCompugen Reports Fourth Quarter and Full Year 2023 ResultsMarch 4, 2024 | benzinga.comEarnings Preview For CompugenFebruary 26, 2024 | finance.yahoo.comCompugen to Present at the Leerink Partners Global Biopharma Conference 2024February 26, 2024 | prnewswire.comCompugen to Present at the Leerink Partners Global Biopharma Conference 2024February 22, 2024 | benzinga.comCompugen Stock (NASDAQ:CGEN), Short Interest ReportFebruary 22, 2024 | benzinga.comCompugen Stock (NASDAQ:CGEN) Dividends: History, Yield and DatesSee More Headlines Receive CGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Compugen and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/05/2024Today5/11/2024Next Earnings (Confirmed)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:CGEN CUSIPN/A CIK1119774 Webwww.cgen.com Phone(723) 765-8585Fax972-3765-8555Employees68Year Founded1993Price Target and Rating Average Stock Price Target$4.00 High Stock Price Target$4.00 Low Stock Price Target$4.00 Potential Upside/Downside+99.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.22) Trailing P/E RatioN/A Forward P/E Ratio100.50 P/E GrowthN/ANet Income$-18,750,000.00 Net MarginsN/A Pretax Margin-29.24% Return on Equity-30.01% Return on Assets-21.41% Debt Debt-to-Equity RatioN/A Current Ratio4.36 Quick Ratio4.36 Sales & Book Value Annual Sales$33.46 million Price / Sales5.20 Cash FlowN/A Price / Cash FlowN/A Book Value$0.76 per share Price / Book2.64Miscellaneous Outstanding Shares86,625,000Free Float78,396,000Market Cap$174.12 million OptionableOptionable Beta2.72 Social Links (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesDr. Anat Cohen-Dayag Ph.D. (Age 57)CEO, President & Director Comp: $796.52kDr. Zurit Levine Ph.D. (Age 56)Senior Vice President of Technology Innovation Comp: $345.7kDr. Pierre Ferre Ph.D. (Age 47)Vice President of Preclinical Development Comp: $415.1kMr. Alberto Sessa (Age 62)Chief Financial Officer Dr. Eran Ophir Ph.D. (Age 46)Chief Scientific Officer Ms. Yvonne NaughtonHead of Investor Relations & Corporate CommunicationsMr. Eran Ben DorGeneral Counsel & Corporate SecretaryMs. Dorit Amitay (Age 56)Vice President of Human Resources Dr. Yaron Turpaz M.B.A. (Age 53)Ph.D., Senior VP & Senior Advisor of Data and Informatics Solutions Rivka SchwartzVice President Research and DiscoveryMore ExecutivesKey CompetitorsElevation OncologyNASDAQ:ELEVOptheaNASDAQ:OPTX4 PharmaceuticalsNASDAQ:XFORZura BioNASDAQ:ZURAAcumen PharmaceuticalsNASDAQ:ABOSView All CompetitorsInstitutional OwnershipTocqueville Asset Management L.P.Sold 30,000 shares on 5/10/2024Ownership: 0.028%Oppenheimer & Co. Inc.Sold 5,000 shares on 5/7/2024Ownership: 0.018%Taylor Frigon Capital Management LLCSold 572,981 shares on 4/19/2024Ownership: 1.526%Matrix Asset Advisors Inc. NYSold 18,823 shares on 4/15/2024Ownership: 0.105%View All Institutional Transactions CGEN Stock Analysis - Frequently Asked Questions Should I buy or sell Compugen stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Compugen in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CGEN shares. View CGEN analyst ratings or view top-rated stocks. What is Compugen's stock price target for 2024? 2 brokerages have issued 12-month target prices for Compugen's stock. Their CGEN share price targets range from $4.00 to $4.00. On average, they anticipate the company's stock price to reach $4.00 in the next year. This suggests a possible upside of 99.0% from the stock's current price. View analysts price targets for CGEN or view top-rated stocks among Wall Street analysts. How have CGEN shares performed in 2024? Compugen's stock was trading at $1.98 at the start of the year. Since then, CGEN stock has increased by 1.5% and is now trading at $2.01. View the best growth stocks for 2024 here. When is Compugen's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our CGEN earnings forecast. How can I listen to Compugen's earnings call? Compugen will be holding an earnings conference call on Monday, May 20th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link. How were Compugen's earnings last quarter? Compugen Ltd. (NASDAQ:CGEN) issued its quarterly earnings data on Tuesday, March, 5th. The biotechnology company reported $0.11 earnings per share for the quarter, beating the consensus estimate of $0.10 by $0.01. The biotechnology company had revenue of $33.46 million for the quarter, compared to the consensus estimate of $60 million. What ETF holds Compugen's stock? ARK Israel Innovative Technology ETF holds 1,066,611 shares of CGEN stock, representing 2.08% of its portfolio. What is Anat Cohen-Dayag's approval rating as Compugen's CEO? 2 employees have rated Compugen Chief Executive Officer Anat Cohen-Dayag on Glassdoor.com. Anat Cohen-Dayag has an approval rating of 100% among the company's employees. This puts Anat Cohen-Dayag in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Compugen own? Based on aggregate information from My MarketBeat watchlists, some companies that other Compugen investors own include Oramed Pharmaceuticals (ORMP), NVIDIA (NVDA), Advanced Micro Devices (AMD), QUALCOMM (QCOM), AbbVie (ABBV), Inovio Pharmaceuticals (INO), Netflix (NFLX), Gilead Sciences (GILD) and Pfizer (PFE). Who are Compugen's major shareholders? Compugen's stock is owned by many different institutional and retail investors. Top institutional shareholders include Taylor Frigon Capital Management LLC (1.53%), Matrix Asset Advisors Inc. NY (0.10%), Tocqueville Asset Management L.P. (0.03%), Oppenheimer & Co. Inc. (0.02%) and Concourse Financial Group Securities Inc. (0.00%). How do I buy shares of Compugen? Shares of CGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CGEN) was last updated on 5/11/2024 by MarketBeat.com Staff From Our PartnersThe Crypto 9-5 Escape PlanCrypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldThe A.I. story nobody is telling you (Read ASAP)TradeSmithTrump’s “Tax Free” Retirement Strategy Gold Safe Exchange"The Biggest Drug Ever" Is ComingBehind the MarketsProtect Your Bank Account Before It’s Too LateWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Compugen Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
